Cargando…
P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429239/ http://dx.doi.org/10.1097/01.HS9.0000849064.31599.55 |
| _version_ | 1784779377468243968 |
|---|---|
| author | Jaeger, U. Broome, C. Go, R. Patriarca, A. Roeth, A. Chang, Q. Weedin, N. Adams, P. Cahir-McFarland, E. Kroon, H.-A. |
| author_facet | Jaeger, U. Broome, C. Go, R. Patriarca, A. Roeth, A. Chang, Q. Weedin, N. Adams, P. Cahir-McFarland, E. Kroon, H.-A. |
| author_sort | Jaeger, U. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429239 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292392022-08-31 P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION Jaeger, U. Broome, C. Go, R. Patriarca, A. Roeth, A. Chang, Q. Weedin, N. Adams, P. Cahir-McFarland, E. Kroon, H.-A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429239/ http://dx.doi.org/10.1097/01.HS9.0000849064.31599.55 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Jaeger, U. Broome, C. Go, R. Patriarca, A. Roeth, A. Chang, Q. Weedin, N. Adams, P. Cahir-McFarland, E. Kroon, H.-A. P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION |
| title | P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION |
| title_full | P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION |
| title_fullStr | P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION |
| title_full_unstemmed | P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION |
| title_short | P1552: A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION |
| title_sort | p1552: a phase 2, open-label study to assess safety, tolerability, and clinical effect of anx005 in patients with warm autoimmune hemolytic anemia and evidence of complement activation |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429239/ http://dx.doi.org/10.1097/01.HS9.0000849064.31599.55 |
| work_keys_str_mv | AT jaegeru p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT broomec p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT gor p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT patriarcaa p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT roetha p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT changq p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT weedinn p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT adamsp p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT cahirmcfarlande p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation AT kroonha p1552aphase2openlabelstudytoassesssafetytolerabilityandclinicaleffectofanx005inpatientswithwarmautoimmunehemolyticanemiaandevidenceofcomplementactivation |